All stock lists
Hims & Hers Health, Inc. (New York Stock Exchange:HIMS)
US · Delayed Price · Currency is USD
Healthcare · Medical - Care Facilities
27.59-0.12 (-0.43%)
Insider Score
––Not scored
HIMS Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
Financial Health Score
Fair
From HIMS’s reported statements · Q2 2026 (trailing 12 months)
Profitability7 / 20
Loses money on what it sells.
- Revenue
- $2.58B
- Net income
- -$142.0M
- Net margin
- -5.5%
Leverage0 / 20
Heavily indebted for what it earns.
- Total debt
- $1.55B
- Cash
- $609.8M
- Debt / equity
- 4.77
Liquidity6 / 20
Owes more within a year than it holds to pay it.
- Current assets
- $1.38B
- Current liabilities
- $1.48B
- Current ratio
- 0.93
Cash generation13 / 20
Roughly cash-neutral.
- Operating cash flow
- $266.8M
- Free cash flow
- $89.9M
- FCF margin
- 3.5%
Dilution & runway17 / 20
Not funding itself by issuing shares.
- Shares outstanding
- 231.7M
- Share growth (1y)
- 3.3%
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
HIMS Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 753.21 M | 608.10 M | 617.82 M | 598.98 M | 544.83 M | 586.01 M |
| Revenue Growth (YoY) | 38.25 % | 3.77 % | 28.41 % | 49.16 % | 72.61 % | 110.67 % |
| Cost of Revenue | 272.41 M | 307.82 M | 173.38 M | 156.92 M | 128.64 M | 155.32 M |
| Gross Profit | 480.80 M | 300.28 M | 444.44 M | 442.06 M | 416.20 M | 430.69 M |
| SG&A Expense | 427.61 M | 331.67 M | 314.21 M | 312.83 M | 285.13 M | 279.85 M |
| R&D Expense | 0.00 | 46.94 M | 40.96 M | 40.58 M | 37.85 M | 29.91 M |
| Operating Expenses | 578.00 M | 316.75 M | 435.25 M | 430.25 M | 389.47 M | 372.79 M |
| Operating Income | -97.19 M | -16.47 M | 9.19 M | 11.81 M | 26.72 M | 57.90 M |
| Pretax Income | -92.63 M | -101.55 M | 18.35 M | 12.22 M | 32.85 M | 60.49 M |
| Tax Provision | -6.34 M | -9.44 M | -2.25 M | -3.55 M | -9.65 M | 11.01 M |
| Net Income | -86.29 M | -92.11 M | 20.60 M | 15.77 M | 42.51 M | 49.48 M |
| EPS (Basic) | -0.37 | -0.40 | 0.09 | 0.07 | 0.19 | 0.22 |
| EPS (Diluted) | -0.37 | -0.40 | 0.08 | 0.06 | 0.17 | 0.20 |
| Shares Outstanding | 231.75 M | 228.36 M | 227.06 M | 226.35 M | 224.37 M | 221.99 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.